Boehringer and partners commence gene therapy trial for cystic fibrosis

Boehringer Ingelheim, the UK Respiratory Gene Therapy Consortium (GTC), IP Group and Oxford BioMedica (OXB) have commenced the Phase I/II LENTICLAIR 1 trial of inhaled lentiviral vector-based gene therapy BI 3720931 targeting cystic fibrosis (CF).